Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × Gemcitabine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 616 Carcinoma, Non-Small-Cell Lung 286 Breast Neoplasms 151 Neoplasms 147 Lung Neoplasms 140 Urinary Bladder Neoplasms 136 Neoplasm Metastasis 122 Cholangiocarcinoma 97 Ovarian Neoplasms 87 Biliary Tract Neoplasms 82 Nasopharyngeal Carcinoma 67 Lymphoma, Large B-Cell, Diffuse 66 Lymphoma 61 Recurrence 55 Sarcoma 54 Gallbladder Neoplasms 54 Hodgkin Disease 48 Carcinoma, Transitional Cell 48 Triple Negative Breast Neoplasms 45 Colorectal Neoplasms 43 Lymphoma, Non-Hodgkin 42 Fallopian Tube Neoplasms 41 Adenocarcinoma 41 Bile Duct Neoplasms 36 Non-Muscle Invasive Bladder Neoplasms 28 Uterine Cervical Neoplasms 27 Unspecified Adult Solid Tumor, Protocol Specific 27 Carcinoma, Ovarian Epithelial 27 Carcinoma 27 Adenocarcinoma of Lung 24

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡